*This information was originally published as part of an abstract for the 2026 MDA Clinical & Scientific Conference*
Understanding Becker Muscular Dystrophy and the Unmet Patient Need
Becker Muscular Dystrophy (BMD) is a rare, progressive neuromuscular disorder caused by mutations in the dystrophin gene, resulting in contraction-induced muscle injury, gradual muscle degeneration, and increased risk of cardiomyopathy. As emerging therapeutics targeting underlying pathophysiologic mechanisms advance through clinical development, standards of care are poised to evolve.
However, in rare diseases such as BMD, therapeutic innovation often outpaces broad clinician awareness. Diagnostic delays, limited exposure to evolving pipelines, and variability in familiarity with mechanism-driven treatment strategies may contribute to gaps between emerging evidence and clinical preparedness. Baseline findings from this initiative demonstrated that the majority of clinicians reported limited awareness of emerging BMD therapies, reinforcing the need for targeted, mechanism-informed education.
As novel agents continue to progress through early-phase trials, practical educational interventions remain essential to ensuring clinicians are prepared to integrate trial-informed insights into real-world care pathways.
The Medlive Approach
To support clinician readiness, Medlive partnered with the National Organization for Rare Disorders (NORD) and the Muscular Dystrophy Association (MDA) to develop a 60-minute CME initiative titled: “Becker Muscular Dystrophy: Hope with Emerging Therapeutics to Reduce Contraction-Induced Injury.”
The activity launched in August 2024 and remained available online for one year. To expand reach beyond traditional CME participation, three short microlearning video segments aligned with the core learning objectives were disseminated via LinkedIn to NPI-verified neurologists.
The curriculum focused on:
- Mechanisms underlying contraction-induced muscle injury in BMD
- The impact of BMD on patient quality of life and long-term outcomes
- Safety and efficacy data for emerging therapeutic agents in development
Educational impact was assessed using pre- and post-activity knowledge and competence questions developed in accordance with National Board of Medical Examiner guidelines. Statistical analyses compared paired responses to evaluate changes in understanding and clinical reasoning.
Key Findings
Broad engagement among neurology-focused clinicians: A total of 4,532 healthcare professionals participated across online and social media platforms, with 83% identifying as neurologists. Nearly half (48%) reported actively treating at least one patient with BMD per week, underscoring strong clinical relevance.
Baseline therapeutic awareness gaps identified: Prior to participation, 56% of learners reported being “not very aware” of emerging therapies, and 22% were “not at all aware,” highlighting substantial unmet educational need.
Significant knowledge and competence gains: Participation in the activity resulted in statistically significant improvements from pre-activity to post-activity (P <0.001) across multiple domains:
- Understanding of contraction-induced muscle injury mechanisms increased from 37% to 57%.
- Identification of cardiomyopathy as the most common cause of mortality in BMD increased from 41% to 61%.
- Recognition of emerging agents in development increased from 29% to 45%.
Case-based assessments evaluating disease trajectory and clinical decision-making also demonstrated significant pre- to post-activity gains (P<0.05), reflecting improved application of knowledge in realistic patient scenarios.
Intent to change practice: Following participation, 52% of clinicians reported intent to modify their practice, most commonly, practice related to treatment approaches and referral patterns.
Reported barriers to implementing changes included insurance or financial limitations (22%), time constraints (19%), and formulary restrictions (18%), reflecting real-world system considerations that may influence adoption of emerging therapies.
Conclusion – Collaborating to Strengthen Clinician Preparedness for Emerging BMD Therapeutics
This outcomes-based CME initiative demonstrated broad engagement among neurology clinicians and measurable improvements in understanding of contraction-induced muscle injury, mortality drivers, and the evolving therapeutic pipeline in BMD.
Baseline findings revealed substantial gaps in awareness of emerging therapies, while post-activity outcomes showed statistically significant knowledge gains and meaningful intent to change practice. Together, these findings underscore the value of targeted, mechanism-driven education in rare neuromuscular disease.
As novel BMD therapies continue to advance, outcomes-focused CME remains an essential strategy to accelerate clinician readiness, support evidence-informed decision-making, and strengthen care pathways for individuals living with rare neuromuscular conditions.
To learn more about partnering with Medlive to develop impactful CME programs in rare disease and neurology, reach out via our Contact Us page.
This activity was supported by an independent educational grant from Edgewise Therapeutics, Inc.
